SCHD, the $100.8 billion Schwab US Dividend Equity ETF, has become a staple allocation for income-focused retirees due to its diversified 100-stock structure and minimal expense ratios. The fund's appeal lies in its cost efficiency and broad exposure to dividend-paying equities across multiple sectors, making it an attractive alternative to manually constructing individual stock portfolios.
A critical structural risk emerges within the fund's top holdings, where at least one constituent faces a significant patent cliff event scheduled post-2028. Patent expirations typically trigger margin compression and revenue headwinds as generic or biosimilar competition materializes, affecting both absolute returns and dividend sustainability. This timing creates a latent revaluation risk embedded in the portfolio that passive holders may not actively monitor.
The concentration risk in SCHD's largest positions amplifies the patent-cliff exposure—while the fund technically holds 100 names, top-four holdings command disproportionate weighting. A material earnings or dividend cut from an affected holding could cascade through the fund's distributions, particularly relevant for retirees dependent on predictable cash flows. This underscores the distinction between passive diversification and active risk management.
Sector implication: Health Care dividend payers—particularly pharmaceutical and biotech names—face cyclical patent-expiration cycles that fundamentally alter their income-generation profiles. Retirees should stress-test the 2028-2030 period for dividend sustainability across Health Care-heavy ETF holdings, as structural headwinds may not be immediately apparent in trailing yield metrics.